Preview: Stepan’s Earnings

Stepan (NYSE:SCL) is set to give its latest quarterly earnings report on Wednesday, 2023-10-18. Here’s what investors need…

Stepan (NYSE:SCL) is set to give its latest quarterly earnings report on Wednesday, 2023-10-18. Here’s what investors need to know before the announcement.

Analysts estimate that Stepan will report an earnings per share (EPS) of $0.82.

Stepan bulls will hope to hear the company announce they’ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Historical Earnings Performance

Last quarter the company missed EPS by $0.64, which was followed by a 0.61% drop in the share price the next day.

Here’s a look at Stepan’s past performance and the resulting price change:

Quarter Q2 2023 Q1 2023 Q4 2022 Q3 2022
EPS Estimate 1.17 0.94 0.54 1.60
EPS Actual 0.53 0.71 0.59 2.01
Price Change % -0.61% -1.4% 2.68% -6.25%

eps graph

Stock Performance

Shares of Stepan were trading at $66.43 as of October 16. Over the last 52-week period, shares are down 34.37%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release.

To track all earnings releases for Stepan visit their earnings calendar on our site.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

‘Psychedelics-Inspired’ Meds For Depression, Anxiety, Addiction Producer Trims Q1 Net Loss YoY, Increases Cash On Hand

Enveric Biosciences reported on Wednesday financial results for the first quarter of 2024 ended March 31, 2024."We believe the first quarter of 2024 was a highly productive period for Enveric as the company continued to advance the development of the lead neuroplastogen drug candidate, EB-003, in preparation for an investigational new drug (IND) application and the expected initiation of a planned clinical development program," Joseph Tucker, Ph.D., director and CEO of Enveric, said. "EB-003 was designed specifically to address this major safety profile deficiency in the first-generation psychedelic approach to treating neuropsychiatric illness, and we are excited to advance its development."

ENVB